Quadrivalent influenza vaccine: A new opportunity to reduce the influenza burden

Journal of Preventive Medicine and Hygiene

Volumn 57, Issue 1, 2016, Pages E28-E33

  Tisa, V ^a   Barberis, I ^a   Faccio, V ^a   Paganino, C ^a   Trucchi, C ^a   Martini, M ^a   Ansaldi, F ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Cost effectiveness; Immunogenicity; Quadrivalent influenza vaccine; Safety

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE;

ARTICLE; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; OUTCOME ASSESSMENT; RISK ASSESSMENT;

EID: 84979265942     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333-40.
2. Lafond KE, Nair H, Rasooly MH, Valente F, Booy R, Rahman M, Kitsutani P, Yu H, Guzman G, Coulibaly D, Armero J, Jima D, Howie SR, Ampofo W, Mena R, Chadha M, Sampurno OD, Emukule GO, Nurmatov Z, Corwin A, Heraud JM, Noyola DE, Cojocaru R, Nymadawa P, Barakat A, Adedeji A, von Horoch M, Olveda R, Nyatanyi T, Venter M, Mmbaga V, Chittaganpitch M, Nguyen TH, Theo A, Whaley M, Azziz-Baumgartner E, Bresee J, Campbell H, Widdowson MA; Global Respiratory Hospitalizations- Influenza Proportion Positive (GRIPP) Working Group. Global Respiratory Hospitalizations-Influenza Proportion Positive (GRIPP) Working Group. Global role and burden of influenza in pediatric respiratory hospitalizations, 1982- 2012: a systematic analysis. PLoS Med 2016;13:e1001977.
3. World Health Organization. Available at: http://www.who.int/mediacentre/factsheets/fs211/en/[Accessed on 10/01/16]
4. Zambon MC. Epidemiology and pathogenesis of influenza. J Antimicrob Chemother 1999;44(Suppl B):3-9.
5. McCullers JA, Wang GC, He S, Webster RG. Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature. J Virol 1999;73:7343-8.
6. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Co-circulation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990;175:59-68.
7. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012;8:81-8.
8. Kheiraoui F, Cadeddu C, Quaranta G, Poscia A, Raponi M, de Waure C, Boccalini S, Pellegrino E, Bellini I, Pieri L, Bechini A, Bonanni P, Barbieri M, Castagna S, Lapinet J, Marinello G, Tosatto R, Silvestri R. Health technology assessment del vaccino antinfluenzale quadrivalente FLU-QIV (Fluarix TetrA®). It J Public Health 2015;4:5.
9. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep 2015;64:818-25.
10. Circular Letter of the Italian Ministry of Health dated on 09/03/2015. Available at: http://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=0&codLeg=52703&parte=1%20&serie=[Accessed on 10/01/16]
11. Ansaldi F, D'Agaro P, De Florentiis D, Puzelli S, Lin YP, Gregory V, Bennett M, Donatelli I, Gasparini R, Crovari P, Hay A, Campello C. Molecular characterization of influenza B viruses circulating in northern Italy during the 2001-2002 epidemic season. J Med Virol 2003;70:463-9.
12. Jennings Z, Carter I, McPhie K, Kok J, Dwyer DE. Increased prevalence of influenza B/Victoria lineage viruses during early stages of the 2015 influenza season in New South Wales, Australia: implications for vaccination and planning. Euro Surveill 2015;20.pii:21201.
13. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, Shay DK; Marshfield Influenza Study Group. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009;199:159-67.
14. Lo YC, Chuang JH, Kuo HW, Huang WT, Hsu YF, Liu MT, Chen CH, Huang HH, Chang CH, Chou JH, Chang FY, Lin TY, Chiu WT. Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011-12 season. PLoS One 2013;8:e58222.
15. Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines 2013;12:1085-94.
16. Fda Available at: http://www.fda.gov/downloads/Advisory- Committees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM167159.pdf [Accessed on 10/01/16]
17. World Health Organization. Summary of status of development and availability of influenza B (Yamagata and Victoria lineage) candidate vaccine viruses∗and potency testing reagents. Available at: http://www.who.int/csr/disease/influenza/summary-b-cvv-reagents-4-may-2011.pdf. [Accessed on 10/01/16]
18. European Medicines Agency issues recommendations for 2012/2013 seasonal flu vaccine composition. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2012/03/news-detail-001467.jsp&mid=WC0b01ac058004d5c1. [Accessed on 20/01/16]
19. Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design casecontrol studies. Lancet Infect Dis 2014;14:1228-39.
20. Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, Belshe RB. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012; 31:745-51.
21. Pebody R, Warburton F, Andrews N, Ellis J, von Wissmann B, Robertson C, Yonova I, Cottrell S, Gallagher N, Green H, Thompson C, Galiano M, Marques D, Gunson R, Reynolds A, Moore C, Mullett D, Pathirannehelage S, Donati M, Johnston J, de Lusignan S, McMenamin J, Zambon M. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill 2015;20:1-11.
22. Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age. Pediatr Infect Dis J 2014;33:1262-9.
23. Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013;207:1878-87.
24. Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, Aggarwal N, Huang LM, Peng CT, Garcia-Sicilia J, Salamanca de la Cueva I, Cabañas F, Treviño-Garza C, Rodríguez-Weber MA, de la O M, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 2013;208:544-53.
25. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥ 18 years. BMC Infect Dis 2013;13:343.
26. Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 2013;31: 5572-8.
27. Regan AK, Tracey L, Gibbs R. Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia. Vaccine 2015;33:6149-51.
28. Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015. Vaccine 2016. pii:S0264-410X(16)30031-7.
29. Eichner M, Schwehm M, Hain J, Uphoff H, Salzberger B, Knuf M, Schmidt-Ott R. 4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany. BMC Infectious Diseases 2014;14:365.
30. Crépey P, de Boer PT, Postma MJ, Pitman R. Retrospective public health impact of a quadrivalent influenza vaccine in the United States. Influenza Other Respir Viruses 2015;9(Suppl 1):39-46.
31. Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One 2014;9:e98437.
32. Meier G, Gregg M, Poulsen Nautrup B. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the UK. J Med Econom 2015;18:746-76.
33. Thommes EW, Ismaila A, Chit A, Meier G, Bauch CT. Costeffectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom. BMC Infect Dis. 2015;15:465.
34. You JH, Ming WK, Chan PK. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis. Hum Vaccin Immunother 2015;11:564-71.
35. Tafalla M, Buijssen M, Geets R, Noordegraaf-Schouten MV. A comprehensive review of the epidemiology and disease burden of influenza B in 9 European countries. Hum Vaccin Immunother 2016:1-10.[Epub ahead of print]
36. van de Sandt CE, Bodewes R, Rimmelzwaan GF, de Vries RD. Influenza B viruses: not to be discounted. Future Microbiol 2015;10:1447-65.
37. Bekkat-Berkani R, Ray R, Jain VK, Chandrasekaran V, Innis BL. Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines. Expert Rev Vaccines 2016;15:201-14.
38. Moore DL; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Vaccine recommendations for children and youth for the 2014/2015 influenza season. Paediatr Child Health 2014;19:440-4.